JP6928963B2 - アンドログラホリドが進化型の多発性硬化症を処置する - Google Patents

アンドログラホリドが進化型の多発性硬化症を処置する Download PDF

Info

Publication number
JP6928963B2
JP6928963B2 JP2018564301A JP2018564301A JP6928963B2 JP 6928963 B2 JP6928963 B2 JP 6928963B2 JP 2018564301 A JP2018564301 A JP 2018564301A JP 2018564301 A JP2018564301 A JP 2018564301A JP 6928963 B2 JP6928963 B2 JP 6928963B2
Authority
JP
Japan
Prior art keywords
multiple sclerosis
group
deoxy
androglaholide
dosage form
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2018564301A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019517550A (ja
JP2019517550A5 (enExample
Inventor
フアン オー． ハンク，
フアン オー． ハンク，
Original Assignee
イノバイオサイエンス， エルエルシー
イノバイオサイエンス， エルエルシー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by イノバイオサイエンス， エルエルシー, イノバイオサイエンス， エルエルシー filed Critical イノバイオサイエンス， エルエルシー
Publication of JP2019517550A publication Critical patent/JP2019517550A/ja
Publication of JP2019517550A5 publication Critical patent/JP2019517550A5/ja
Priority to JP2021113384A priority Critical patent/JP2021165304A/ja
Application granted granted Critical
Publication of JP6928963B2 publication Critical patent/JP6928963B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/01—Hydrocarbons
    • A61K31/015—Hydrocarbons carbocyclic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/19—Acanthaceae (Acanthus family)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Hospice & Palliative Care (AREA)
  • Molecular Biology (AREA)
  • Mycology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Medical Informatics (AREA)
  • Botany (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2018564301A 2016-06-08 2017-06-08 アンドログラホリドが進化型の多発性硬化症を処置する Active JP6928963B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2021113384A JP2021165304A (ja) 2016-06-08 2021-07-08 アンドログラホリドが進化型の多発性硬化症を処置する

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662347218P 2016-06-08 2016-06-08
US62/347,218 2016-06-08
PCT/US2017/036463 WO2017214346A1 (en) 2016-06-08 2017-06-08 Andrographolide treats progressive forms of multiple sclerosis

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2021113384A Division JP2021165304A (ja) 2016-06-08 2021-07-08 アンドログラホリドが進化型の多発性硬化症を処置する

Publications (3)

Publication Number Publication Date
JP2019517550A JP2019517550A (ja) 2019-06-24
JP2019517550A5 JP2019517550A5 (enExample) 2020-07-09
JP6928963B2 true JP6928963B2 (ja) 2021-09-01

Family

ID=60578163

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2018564301A Active JP6928963B2 (ja) 2016-06-08 2017-06-08 アンドログラホリドが進化型の多発性硬化症を処置する
JP2021113384A Pending JP2021165304A (ja) 2016-06-08 2021-07-08 アンドログラホリドが進化型の多発性硬化症を処置する

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2021113384A Pending JP2021165304A (ja) 2016-06-08 2021-07-08 アンドログラホリドが進化型の多発性硬化症を処置する

Country Status (8)

Country Link
US (1) US10722492B2 (enExample)
EP (1) EP3468553B1 (enExample)
JP (2) JP6928963B2 (enExample)
CN (1) CN109562097B (enExample)
CA (1) CA3026770C (enExample)
DK (1) DK3468553T3 (enExample)
MX (1) MX386393B (enExample)
WO (1) WO2017214346A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019126759A1 (en) * 2017-12-22 2019-06-27 Convelo Therapeutics, Inc. Compounds and methods of promoting myelination
CN109293607A (zh) * 2018-11-14 2019-02-01 株洲千金药业股份有限公司 一种具有抗炎作用的化合物及其在制备抗炎药物中的应用
CN109223770A (zh) * 2018-11-14 2019-01-18 株洲千金药业股份有限公司 一种具有镇痛作用的化合物及其在制备镇痛药物中的应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003059387A2 (en) * 2001-12-21 2003-07-24 Ilex Oncology, Inc. Combination comprising anti-cd52 antibodies and other therapeutic agents for treatment for multiple sclerosis
KR20070026398A (ko) * 2004-02-03 2007-03-08 우니베르시다드 오스뜨랄 데 칠레 Ｐｐａｒ-감마 수용체의 활성화에 의한 자가면역 질환 및알츠하이머병의 치료에 유용한, 천심련으로부터 추출된랍단 디테르펜을 포함하는 조성물
JP5936707B2 (ja) * 2011-12-21 2016-06-22 イノバイオサイエンス， エルエルシー インターフェロンおよびアンドログラホリドを用いた多発性硬化症のための併用療法

Also Published As

Publication number Publication date
EP3468553A4 (en) 2020-02-12
CN109562097B (zh) 2022-06-07
EP3468553B1 (en) 2023-05-24
EP3468553A1 (en) 2019-04-17
US20190083458A1 (en) 2019-03-21
US10722492B2 (en) 2020-07-28
DK3468553T3 (da) 2023-07-03
JP2021165304A (ja) 2021-10-14
MX386393B (es) 2025-03-18
WO2017214346A1 (en) 2017-12-14
JP2019517550A (ja) 2019-06-24
CA3026770C (en) 2024-05-28
CA3026770A1 (en) 2017-12-14
CN109562097A (zh) 2019-04-02
MX2018015208A (es) 2019-09-19

Similar Documents

Publication Publication Date Title
US20200338097A1 (en) Use of a heterocyclic bcl-2 inhibitor for removing senescent cells and treating senescence-associated conditions
JP2021165304A (ja) アンドログラホリドが進化型の多発性硬化症を処置する
CN117377476B (zh) 治疗与化学疗法诱发的周围神经病变相关的疼痛
US20230146896A1 (en) Composition and method for treating alzheimer's disease
US12318380B2 (en) Treatment of demyelinating diseases
CN110300581A (zh) 具有奇数碳的脂类化合物及其作为医药组合物或者营养补充剂的用途
Elgazzar et al. RETRACTED: Neurotoxic effects of pregabalin dependence on the brain frontal cortex in adult male albino rats
JP2024524679A (ja) アルツハイマー病の処置方法
EP2872217A1 (en) Treatment of multiple sclerosis with combination of laquinimod and fampridine
TW201204360A (en) Treatment of multiple sclerosis with MASITINIB
Yang et al. Anti-epileptic and neuroprotective effects of ultra-low dose NADPH oxidase inhibitor dextromethorphan on kainic acid-induced chronic temporal lobe epilepsy in rats
JP5936707B2 (ja) インターフェロンおよびアンドログラホリドを用いた多発性硬化症のための併用療法
Shrivastava et al. A review of current status of epilepsy after traumatic brain injuries: Pathophysiology, clinical outcomes, and emerging treatment strategies
CA3238640A1 (en) Method for treating cancer with acylfulvene and radiation
WO2022052016A1 (en) Pharmaceutical compositions and uses thereof in treating parkinson's disease
RU2805061C2 (ru) Лечение демиелинизирующих заболеваний
CN115052595B (en) Novel therapeutic methods for treating neurological diseases or disorders
Kang et al. Matrine protects retinal ganglion cells from apoptosis in experimental optic neuritis
JP2025503457A (ja) 神経系損傷及び障害の治療のための安息香酸塩

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200521

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20200521

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210412

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210708

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20210730

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20210802

R150 Certificate of patent or registration of utility model

Ref document number: 6928963

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20210708

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250